v3.25.2

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 8,430,946	$ 63,741
Prepaid expenses	115,386	94,070
Total current assets	8,546,332	157,811
Other assets:
Licenses	2,251,134	2,251,134
Patents	48,420	48,420
Total other assets	2,299,554	2,299,554
Total assets	10,845,886	2,457,365
Current liabilities:
Accounts payable	12,631	63,686
Accrued expenses	50,331	912,095
Notes payable		240,753
Total current liabilities	62,962	1,247,534
Warrant liability	132,447	24,486
Total liabilities	195,409	1,272,020
Commitments and contingencies (Note 10)
STOCKHOLDERS’ EQUITY
Preferred stock, par value $0.0001, 100,000,000 shares authorized; 500 and 0 issued and outstanding as of June 30, 2025 and December 31, 2024, respectively
Common stock, par value $0.0001, 1,000,000,000 shares authorized; 52,703,070 and 27,080,915 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively	5,270	2,708
Additional paid-in capital	27,535,219	11,745,436
Accumulated deficit	(16,890,012)	(10,562,799)
Total stockholders’ equity	10,650,477	1,185,345
Total liabilities and stockholders’ equity	10,845,886	2,457,365
Related Party
Current liabilities:
Notes payable to related parties		$ 31,000

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Klotho Neurosciences, Inc. 10-Q